These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 8676708)
1. Guidance on new therapies in multiple sclerosis patients. Gonsette RE Lancet; 1996 Jul; 348(9020):136. PubMed ID: 8676708 [No Abstract] [Full Text] [Related]
2. Treatment of multiple sclerosis and related disorders: what's new in the past 2 years? Noseworthy JH Clin Neuropharmacol; 2003; 26(1):28-37. PubMed ID: 12567162 [No Abstract] [Full Text] [Related]
3. [Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept]. Kornhuber ME; Zierz S Nervenarzt; 2003 Jun; 74(6):537-8; discussion 539. PubMed ID: 12799792 [No Abstract] [Full Text] [Related]
4. [Multiple sclerosis (MS), an inflammatory or degenerative disease?]. Confavreux C; Vukusic S Presse Med; 2004 Feb; 33(3):151-2. PubMed ID: 15029024 [No Abstract] [Full Text] [Related]
5. New treatments for multiple sclerosis. Hutchinson M Ir Med J; 1996; 89(2):44. PubMed ID: 8682623 [No Abstract] [Full Text] [Related]
9. [Multiple sclerosis]. Itoyama Y No To Shinkei; 2000 Dec; 52(12):1051-5. PubMed ID: 11193536 [No Abstract] [Full Text] [Related]
10. The treatment of multiple sclerosis: current and future. Polman CH; Hartung HP Curr Opin Neurol; 1995 Jun; 8(3):200-9. PubMed ID: 7551119 [TBL] [Abstract][Full Text] [Related]
11. Seeing injectable ms therapies differently: they are more similar than different. Johnson KP; Fox RJ; Arnold DL Neurology; 2010 Feb; 74(8):702. PubMed ID: 20177129 [No Abstract] [Full Text] [Related]
12. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes. Frohman EM; Racke M; van Den Noort S Arch Neurol; 2000 Jul; 57(7):930-2. PubMed ID: 10891973 [No Abstract] [Full Text] [Related]
13. [Problems and prospects of beta-interferon and copaxone++ application in the treatment of multiple sclerosis]. Gusev EI; Boĭko AN; Pozer Ch Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(4):33-6. PubMed ID: 10319395 [No Abstract] [Full Text] [Related]
15. Disease modifying treatment in multiple sclerosis. Fuller GN; Bone I J Neurol Neurosurg Psychiatry; 2001 Dec; 71 Suppl 2(Suppl 2):ii20-1. PubMed ID: 11701780 [No Abstract] [Full Text] [Related]
16. What is new in the treatment of multiple sclerosis? Weinstock-Guttman B; Jacobs LD Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827 [TBL] [Abstract][Full Text] [Related]
17. Disease-modifying drugs for the early treatment of multiple sclerosis. Flachenecker P Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542 [TBL] [Abstract][Full Text] [Related]
18. Current disease-modifying therapies in multiple sclerosis. Kieseier BC; Hartung HP Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379 [TBL] [Abstract][Full Text] [Related]
19. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review. Clegg A; Bryant J; Milne R Health Technol Assess; 2000; 4(9):i-iv, 1-101. PubMed ID: 10944743 [No Abstract] [Full Text] [Related]
20. Biogen wins Euro MS approval, but loses patents. Brower V Nat Biotechnol; 1997 May; 15(5):410. PubMed ID: 9131611 [No Abstract] [Full Text] [Related] [Next] [New Search]